XML 105 R5.htm IDEA: XBRL DOCUMENT v3.19.2
CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY - USD ($)
$ in Thousands
Total
Series B Convertible Preferred Stock [Member]
Series C Convertible Preferred Stock [Member]
Convertible Preferred Stock [Member]
Convertible Preferred Stock [Member]
Series B Convertible Preferred Stock [Member]
Convertible Preferred Stock [Member]
Series C Convertible Preferred Stock [Member]
Common Stock [Member]
Common Stock [Member]
Series B Convertible Preferred Stock [Member]
Common Stock [Member]
Series C Convertible Preferred Stock [Member]
Additional Paid-in Capital [Member]
Additional Paid-in Capital [Member]
Series B Convertible Preferred Stock [Member]
Additional Paid-in Capital [Member]
Series C Convertible Preferred Stock [Member]
Accumulated Other Comprehensive Income [Member]
Accumulated Deficit [Member]
Balance at Dec. 31, 2016 $ 10,986                 $ 388,791     $ 1,258 $ (379,063)
Balance (in shares) at Dec. 31, 2016             43,416              
Share-based compensation 753                 753        
Issuance of common stock under employee stock purchase plan 1                 1        
Issuance of common stock under employee stock purchase plan (in shares)             2              
Sale/Issuance of common stock 12,716 $ 8,767               12,716 $ 8,767      
Sale/Issuance of common stock (in shares)         10,000   24,474              
Conversion of Convertible Preferred Stock into common stock   23                 23      
Conversion of Convertible Preferred Stock into common stock (share)         (7,569)     45,413            
Issuance of common stock as part of Azaya Therapeutics acquisition, net 2,311                 2,311        
Issuance of common stock as part of Azaya Therapeutics acquisition, net (shares)             2,346              
Beneficial conversion feature related to Series B Convertible Preferred Stock   3,977                 3,977      
Accretion of beneficial conversion feature related to Series B Convertible Preferred Stock   $ (3,977)                 $ (3,977)      
Foreign currency translation adjustment and accumulated other comprehensive income 129                       129  
Net loss (22,686)                         (22,686)
Balance at Dec. 31, 2017 $ 13,000                 413,362     1,387 (401,749)
Balance (in shares) at Dec. 31, 2017 115,651     2,431     115,651              
Share-based compensation $ 143                 143        
Sale/Issuance of common stock 27                 27        
Sale/Issuance of common stock (in shares)             201              
Conversion of Convertible Preferred Stock into common stock (share)         (1,228)     7,375            
Foreign currency translation adjustment and accumulated other comprehensive income (281)                       (281)  
Net loss (4,409)                         (4,409)
Balance at Mar. 31, 2018 8,480                 413,532     1,106 (406,158)
Balance (in shares) at Mar. 31, 2018       1,203     123,227              
Balance at Dec. 31, 2017 $ 13,000                 413,362     1,387 (401,749)
Balance (in shares) at Dec. 31, 2017 115,651     2,431     115,651              
Share-based compensation $ 355                 355        
Sale/Issuance of common stock 1,624   $ 3,041             1,624   $ 3,041    
Sale/Issuance of common stock (in shares)           6,723 92,169              
Conversion of Convertible Preferred Stock into common stock     8                 8    
Conversion of Convertible Preferred Stock into common stock (share)         (1,320) (3,228)   7,921 80,868          
Beneficial conversion feature related to Series B Convertible Preferred Stock     2,487                 2,487    
Accretion of beneficial conversion feature related to Series B Convertible Preferred Stock     $ (2,487)                 $ (2,487)    
Foreign currency translation adjustment and accumulated other comprehensive income (169)                       (169)  
Net loss (12,634)                         (12,634)
Balance at Dec. 31, 2018 $ 5,225                 418,390     1,218 (414,383)
Balance (in shares) at Dec. 31, 2018 296,609     4,606     296,609              
Share-based compensation $ 49                 49        
Sale/Issuance of common stock 1,873                 1,873        
Sale/Issuance of common stock (in shares)             139,855              
Conversion of Convertible Preferred Stock into common stock (share)           (66)     1,652          
Foreign currency translation adjustment and accumulated other comprehensive income (140)                       (140)  
Net loss (3,150)                         (3,150)
Balance at Mar. 31, 2019 $ 3,857                 $ 420,312     $ 1,078 $ (417,533)
Balance (in shares) at Mar. 31, 2019 438,116     4,540     438,116